Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.

Brümmendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH.

Br J Haematol. 2016 Jan;172(1):97-110. doi: 10.1111/bjh.13801. Epub 2015 Nov 4.

2.

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.

Gomez HL, Philco M, Pimentel P, Kiyan M, Monsalvo ML, Conlan MG, Saikali KG, Chen MM, Seroogy JJ, Wolff AA, Escandon RD.

Anticancer Drugs. 2012 Mar;23(3):335-41. doi: 10.1097/CAD.0b013e32834e74d6.

PMID:
22123335
3.

A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.

Souid AK, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, Adamson PC.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1323-8. doi: 10.1002/pbc.22609. Epub 2010 Aug 13.

4.

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.

Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG.

Transfusion. 2006 Oct;46(10):1693-704.

PMID:
17002625
5.

Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.

Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan MG.

Transfusion. 2006 May;46(5):731-40.

PMID:
16686840
6.

Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.

Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, Porter S, Lin L, Metzel P, Conlan MG; SPRINT Study Group.

Transfusion. 2006 Apr;46(4):562-71.

PMID:
16584432
7.

Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.

Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, Lin L, Sørensen H, Borregaard N, Flament J.

Transfusion. 2006 Mar;46(3):424-33.

PMID:
16533286
8.

Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.

Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin JS, Corash L, Conlan MG; SPRINT Study Group.

Transfusion. 2006 Jan;46(1):24-33.

PMID:
16398727
9.

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.

Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG; SPRINT Study Group.

Transfusion. 2005 Dec;45(12):1864-75.

PMID:
16371039
10.

Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.

Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG.

Transfusion. 2005 Nov;45(11):1739-49.

PMID:
16271099
11.

Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.

Lin L, Conlan MG, Tessman J, Cimino G, Porter S.

Transfusion. 2005 Oct;45(10):1610-20. Review.

PMID:
16181212
12.

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

Janetzko K, Cazenave JP, Klüter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J.

Transfusion. 2005 Sep;45(9):1443-52.

PMID:
16131376
13.

Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.

Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, Baril L, Davis K, Buchholz DH, Corash L, Conlan MG.

Transfusion. 2004 Dec;44(12):1732-40.

PMID:
15584988
14.

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG.

Blood. 2004 Sep 1;104(5):1534-41. Epub 2004 May 11.

15.

Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.

Conlan MG, Folsom AR, Finch A, Davis CE, Marcucci G, Sorlie P, Wu KK.

Thromb Haemost. 1994 Oct;72(4):551-6.

PMID:
7878631
16.

Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.

Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK.

Thromb Haemost. 1993 Nov 15;70(5):762-7.

PMID:
8128432
17.

Quantitative analysis of vascular prostaglandin H synthase mRNA levels by competitive polymerase chain reaction.

Zyglewska T, Wu LC, Xu XM, Conlan MG, Wang LH, Wu KK.

J Lab Clin Med. 1993 Nov;122(5):542-8.

PMID:
8228572
18.

Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.

Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK.

Thromb Haemost. 1993 Sep 1;70(3):380-5.

PMID:
8259533
19.

Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The Atherosclerosis Risk in Communities (ARIC) Study.

Shahar E, Folsom AR, Wu KK, Dennis BH, Shimakawa T, Conlan MG, Davis CE, Williams OD.

Arterioscler Thromb. 1993 Aug;13(8):1205-12.

PMID:
8343495

Supplemental Content

Loading ...
Support Center